Related references
Note: Only part of the references are listed.Arsenic trioxide downregulates specificity protein (Sp) transcription factors and inhibits bladder cancer cell and tumor growth
Indira Jutooru et al.
EXPERIMENTAL CELL RESEARCH (2010)
Drugs that Target Specificity Proteins Downregulate Epidermal Growth Factor Receptor in Bladder Cancer Cells
Gayathri Chadalapaka et al.
MOLECULAR CANCER RESEARCH (2010)
Oncogenic microRNA-27a is a target for anticancer agent methyl 2-cyano-3,11-dioxo-18β-olean-1,12-dien-30-oate in colon cancer cells
Sudhakar Chintharlapalli et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Sp1, a new biomarker that identifies a subset of aggressive pancreatic ductal adenocarcinoma
Naomi Y. Jiang et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2008)
Curcumin decreases specificity protein expression in bladder cancer cells
Gayathri Chadalapaka et al.
CANCER RESEARCH (2008)
Phase II trial of curcumin in patients with advanced pancreatic cancer
Navneet Dhillon et al.
CLINICAL CANCER RESEARCH (2008)
Rapid reactive oxygen species (ROS) generation induced by curcumin leads to caspase-dependent and -independent apoptosis in L929 cells
Faisal Thayyullathil et al.
FREE RADICAL BIOLOGY AND MEDICINE (2008)
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells
Michael Sun et al.
MOLECULAR CANCER THERAPEUTICS (2008)
The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells
Susanne U. Mertens-Talcott et al.
CANCER RESEARCH (2007)
Role of specificity protein transcription factors in estrogeninduced gene expression in MCF-7 breast cancer cells
Shaheen Khan et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2007)
Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products
Ajaikumar B. Kunnumakkara et al.
CANCER RESEARCH (2007)
Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells
Maen Abdelrahim et al.
CANCER RESEARCH (2007)
Betulinic acid inhibits prostate cancer growth through inhibition of specificity protein transcription factors
Sudhakar Chintharlapalli et al.
CANCER RESEARCH (2007)
Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression
D. S. Basseres et al.
ONCOGENE (2006)
Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins
Kelly J. Higgins et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation
Maen Abdelrahim et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
NF-κB and cancer:: Mechanisms and targets
Michael Karin
MOLECULAR CARCINOGENESIS (2006)
Liposome-encapsulated curcumin - In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis
L Li et al.
CANCER (2005)
NF-κB site interacts with Sp factors and up-regulates the NR1 promoter during neuronal differentiation
AG Liu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Role of Sp proteins in regulation of vascular endothelial growth factor expression and proliferation of pancreatic cancer cells
M Abdelrahim et al.
CANCER RESEARCH (2004)
Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II trial
HQ Xiong et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Nuclear factor-κB and IκB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis
L Li et al.
CANCER (2004)
Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group
MJ Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Chemotherapy for advanced pancreatic cancer
DG Haller
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2003)
The medical management of pancreatic cancer: A review
S McKenna et al.
ONCOLOGIST (2003)
Pancreatic cancer: From genes to patient care
RH Hruban
JOURNAL OF GASTROINTESTINAL SURGERY (2001)
Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial
SR Bramhall et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Angiogenesis inhibitor TNP-470 reduces human pancreatic cancer growth
HG Hotz et al.
JOURNAL OF GASTROINTESTINAL SURGERY (2001)
Share Paper
